Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sanford Burnham Prebys","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanford Burnham Prebys Announces Start Of Phase 2 Clinical Trial Of DS-1211 In Individuals With PseudoXanthoma Elasticum","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for N-Acetyl-D-Leucine

    Menu

    N-Acetyl-D-Leucine

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    MARKET PLACE

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Daiichi Sankyo

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sanford Burnham Prebys Announces Start Of Phase 2 Clinical Trial Of DS-1211 In Individuals With PseudoXanthoma Elasticum

              Details:

              DS-1211 is a potent and specific small-molecule inhibitor of TNAP. In vitro studies characterized the mode of inhibition and inhibitory effects of DS-1211 on three human ALP isozymes-TNAP, human intestinal ALP, human placental ALP.

              Lead Product(s): N-Acetyl-D-Leucine

              Therapeutic Area: Genetic Disease Product Name: DS-1211

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sanford Burnham Prebys

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY